Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Condition(s):Locally Advanced Malignant Neoplasm; Oral Cancer; Oropharyngeal Carcinoma; Effects of ChemotherapyLast Updated:August 21, 2017Completed
Hide Studies Not Open or Pending
Condition(s):Locally Advanced Malignant Neoplasm; Oral Cancer; Oropharyngeal Carcinoma; Effects of ChemotherapyLast Updated:August 21, 2017Completed
Condition(s):Locally Advanced Malignant Neoplasm; Oral Cancer; Oropharyngeal CarcinomaLast Updated:May 5, 2020Completed
Condition(s):HER2+ Breast CancerLast Updated:July 5, 2023Completed
Condition(s):Triple Negative Breast Cancer PatientsLast Updated:October 25, 2017Completed
Condition(s):Gastroesophageal Junction Adenocarcinoma; Stomach NeoplasmsLast Updated:April 26, 2023Active, not recruiting
Condition(s):Urothelial Carcinoma; CancerLast Updated:May 30, 2023Recruiting
Condition(s):Rectal Cancer; Rectal NeoplasmLast Updated:January 20, 2017Withdrawn
Condition(s):Breast CancerLast Updated:February 15, 2021Completed
Condition(s):Breast CancerLast Updated:July 27, 2010Unknown status
Condition(s):HER2-negative Breast Cancer; Neoadjuvant Therapy; Pathological Complete Response; Immunotherapy; Vinorelbine; CisplatinLast Updated:October 18, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.